Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference124 articles.
1. Paving the road to MRD-guided treatment in CLL;Bottcher;Blood,2014
2. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?;Dreger;Blood,2014
3. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia;Byrd;N Engl J Med,2013
4. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia;Furman;N Engl J Med,2014
5. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial;Zenz;Blood,2009
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Advances in adoptive T-cell therapy for metastatic melanoma;Current Research in Translational Medicine;2023-07
2. Nestin Regulates Keap1-Nrf2-HO-1-Mediated Antioxidant Responses during Stress and Malignant Hematopoiesis;BioMed Research International;2022-05-28
3. Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence;Journal of Translational Medicine;2021-11-22
4. Functional Differences Between EBV- and CMV-Specific CD8+ T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL;HemaSphere;2020-02-13
5. CAR-T Cell Clinical Trials Experience – Past, Present and Future;Second Generation Cell and Gene-based Therapies;2020
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3